Is Veradermics, Incorporated (MANE) a Buy, Sell, or Hold?
NYSE : MANE
Veradermics, Incorporated
$109.51 USD
-$6.35 (-5.48%)
- Volume
- 532.99K
- Average Volume
- 710.64K
- Market Capitalization
- $4.58B
- P/E Ratio
- -70.20
- Dividend Yield
- 0.00%
- Price Target
- $170.00
- Year High
- $131.24
- Year Low
- $32.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $59.12
Company Overview
NYSE
Reid Waldman
Biotechnology
Healthcare
MANE
21
US
USD
Liquidity Metrics
0.00
59.12
59.12
25.08
0.00
Sales & Valuation
-$
0.00
10.43
-102.12
-1.20
Profitability
-$2.38
-$70M
0.00%
0.00%
-84.21%
-12.31%
P/E Metrics
-70.20
-0.70
-0.70
Analyst Price Target & Rating
$170.00
$182.00
$136.00
1/5
4 Analysts
-35.58%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
$4.41B
0.00
-90.77
59.12
-84.21%
-13.49%
-1.20%
-0.98%
0 days
Company Executives
| Name | Title |
|---|---|
| Timothy Durso | Chief Technical Officer |
| Mark Neumann | Chief Commercial and Strategy Officer |
| Michael Murphy | VP of Project & Program Management of Business Technology and Chief of Staff |
| Aron Shapiro | Vice President of Clinical Development & Regulatory Affairs |
| Brian Trautman | Director of CMC Project Management |
| Karl Pruss | Senior Director of Manufacturing Sciences & Technology |
| Michael V. Greco | General Counsel & Secretary |
| Erika Sipperly | Controller |
| Reid Waldman | CEO & Director |
| Dominic Carrano | CFO & Treasurer |
| Michael Smolinski | Vice President of Development & Scientific Operations |
Poll Results
No votes yet today — be the first to share your view!
About Veradermics, Incorporated (NYSE:MANE) Stock
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as andro ... genetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Veradermics: VDPHL01 Looks Promising Enough On Paper
2026-07-17 08:40:35
MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.
2026-07-17 07:30:00
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during th.
Veradermics (NYSE:MANE) Shares Gap Up After Analyst Upgrade
2026-07-17 04:27:36
Veradermics, Incorporated (NYSE: MANE - Get Free Report)'s stock price gapped up before the market opened on Wednesday after Citigroup raised their price target on the stock from $135.00 to $160.00. The stock had previously closed at $110.17, but opened at $118.75. Citigroup currently has a buy rating on the stock. Veradermics shares last traded at
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
2026-07-15 13:47:44
Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss.
2026-07-15 13:07:57
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
2026-07-15 10:05:21
Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment.
2026-07-15 07:00:00
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from its open-label Phase 2 clinical trial (Study ‘207') evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss. VDPHL01 has the potential to become the first FDA-approved oral.
2026-07-14 18:54:00
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207' evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-.
Frequently Asked Questions
-
What is the current Veradermics, Incorporated (MANE) stock price?
-
Veradermics, Incorporated(NYSE:MANE) stock price is $109.51 in the last trading session. During the trading session, MANE stock reached the peak price of $131.24 while $32 was the lowest point it dropped to. The percentage change in MANE stock occurred in the recent session was --5.48% while the dollar amount for the price change in MANE stock was -$6.35.
-
MANE's industry and sector of operation?
-
The NYSE listed MANE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MANE?
-
Timothy Durso | Chief Technical Officer
Mark Neumann | Chief Commercial and Strategy Officer
Michael Murphy | VP of Project & Program Management of Business Technology and Chief of Staff
Aron Shapiro | Vice President of Clinical Development & Regulatory Affairs
Brian Trautman | Director of CMC Project Management -
How many employees does MANE have?
-
Number of MANE employees currently stands at 21. MANE operates from 470 James Street, New Haven, CT 06513, US.
-
Link for MANE official website?
-
Official Website of MANE is: https://www.veradermics.com
-
How do I contact MANE?
-
MANE could be contacted at phone #(228) 372-3376 and can also be accessed through its website. MANE operates from 470 James Street, New Haven, CT 06513, US.
-
How many shares of MANE are traded daily?
-
The average number of MANE shares traded daily for last 3 months was 710.64K.
-
What is the market cap of MANE currently?
-
The market value of MANE currently stands at $4.58B with its latest stock price at $109.51